Shots:
- Genentech has reported the P-III (MAJESTY) trial results assessing Gazyva vs tacrolimus in 142 pts with primary membranous nephropathy
- Trial met its 1EP, showing higher CR at Wk. 104 & achieved its key 2EPs, incl. improved overall remission & CR at Wks. 104 & 76, respectively; data to be presented in the future & shared with health authorities, incl. the US FDA & EMA
- Gazyva is also being investigated in a global P-II study for pediatric lupus nephritis
Ref: Genentech  | Image: Genentech  | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
